
Research · Cancer Education
Upper GI Cancers at ASCO 2026: A New HER2-Positive Standard, a Negative Dual-IO Trial, and Two Signals From Asia
Upper GI cancers remain among the most lethal malignancies worldwide, and the treatment landscape has been evolving rapidly since the approvals of trastuzumab in HER2-positive disease and checkpoint inhibitors across the HER2-negative population.
By Dr. Ronan Hsieh





























